The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index; 7 of the 16 sources its claims cite were checked for support.
Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.
Open accessAbstract
Initial clinical trial results showed safe, feasible, and reversible focused-ultrasound BBB opening in the hippocampus and entorhinal cortex of early AD patients.
Overview
CoChat Summary
## TL;DR
This open-label phase II trial reports that MR-guided low-intensity focused ultrasound (FUS) can safely, reversibly, and repeatedly open the blood-brain barrier (BBB) in the hippocampus/entorhinal cortex of patients with early Alzheimer’s disease. In 6 participants and 17 treatment sessions, BBB opening was immediate, sizable, and transient, with no treatment-related adverse effects or neurological worsening reported.
## Key findings
- Six participants (5 female, 1 male; ages 55–73) underwent a total of 17 FUS treatment sessions targeting the hippocampus/entorhinal cortex.
- All 17 sessions produced immediate hippocampal parenchymal enhancement on contrast MRI, indicating BBB opening, with no off-target enhancement.
- BBB opening resolved within 24 hours after treatment.
- MRI-based volumetric analysis found BBB opening covered 95 ± 4% of the FUS-targeted volume, ranging from 318 mm³ to 873 mm³, corresponding to 14% to 71% of the overall hippocampal volume, with an average of 29%.
- There were no treatment-related adverse effects or neurological changes up to 15 months post-FUS, and formal cognitive assessments at 30 days after the last treatment in the first five subjects showed no clinically meaningful changes.
## Methods
- Design: Open-label, prospective phase II clinical trial sponsored by INSIGHTEC, with repeated MR-guided low-intensity FUS to the hippocampus and entorhinal cortex.
- Sample/data: 6 patients with early AD enrolled at two sites (West Virginia University Rockefeller Neuroscience Institute, n=4; Weill Cornell Medical College, n=2), diagnosed by NIA-AA criteria and with 18F-florbetaben PET consistent with AD and amyloid-beta plaques in the target.
- Main analysis: FUS was delivered with simultaneous IV microbubbles; safety was assessed with neurological exams and T2* MRI for hemorrhage, and BBB opening was evaluated by post-FUS gadobutrol contrast MRI with manual segmentation and comparison to targeted and overall hippocampal volumes.
## Limitations
- The paper frames these as initial/early outcomes from an ongoing multicenter trial, so efficacy conclusions are not yet established.
- The study includes only 6 participants and 17 treatments, which limits generalizability; this limitation is evident from the text.
- The paper reports safety/feasibility and imaging-based BBB opening, but does not state clinical benefit on cognition or AD progression beyond “no clinically meaningful changes” in short-term assessments; this limitation is evident from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
6 Valid · 0 Not valid · 2 Not checked · 23 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Animal studies have demonstrated safe and reversible BBB opening (4, 6, 7) as well as reduction of amyloid-beta plaque, neurogenesis, and improvement of memory.”
§ Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] source
- Supportedcites [6] source
The Introduction describes focused-ultrasound BBB opening as temporary and says it can be achieved safely. The Discussion reports that repeated BBB opening in the study's mice caused no histologic signs of tissue damage. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [7] source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MRI-based volumetric analysis of BBB opening in the hippocampus demonstrated parenchymal contrast enhancement of 95 ± 4% of the FUS targeted volume, ranging from 318 mm3 (two targets) to 873 mm3 (five targets).”
§ Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound > Results
boostedn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This parenchymal contrast enhancement resolved within 24 h after FUS treatment.”
§ Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Formal cognitive assessments at 30 d after the last treatment in the first five subjects showed no clinically meaningful changes (SI Appendix).”
§ Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound > Results
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MRI with gadobutrol IV contrast post-FUS treatment revealed immediate hippocampal parenchymal enhancement at the target region in all 17 treatment sessions, indicating enhanced BBB permeability, with no off-target enhancement (Fig. 2).”
§ Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound > Results
plainstates a causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 31 claims and every source verdict.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950 · cited 2×
“This study is the next step following a proof of concept phase I study in AD patients demonstrating safe BBB opening in a limited noneloquent white matter area of the superficial dorsolateral prefrontal cortex (11).”
BackgroundResultThe role of adult hippocampal neurogenesis in brain health and disease
Toda, T., Parylak, S. L., Linker, S. B., & Gage, F. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0036-2 · Cited by 719 · cited 1×
“T hippocampus is critical in the pathogenesis of Alzheimer’s disease (AD), epilepsy, and depression (1).”
BackgroundScanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · cited 1×
“FUS-mediated BBB opening in preclinical models has been found to promote amyloid-beta clearance, delivery of endogenous antibodies, activation of microglia (8, 12), and potential modulation of the glymphatic system (13).”
BackgroundBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405 · cited 1×
“To overcome the BBB, pharmaceuticals and biological treatments require systemic dose escalation or invasive, risky procedures like transarterial diuretic infusion and direct intracranial infusion (2, 3).”
BackgroundEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387 · cited 1×
“To overcome the BBB, pharmaceuticals and biological treatments require systemic dose escalation or invasive, risky procedures like transarterial diuretic infusion and direct intracranial infusion (2, 3).”
BackgroundJordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326 · cited 1×
“FUS-mediated BBB opening in preclinical models has been found to promote amyloid-beta clearance, delivery of endogenous antibodies, activation of microglia (8, 12), and potential modulation of the glymphatic system (13).”
BackgroundKrishna, V., Sammartino, F., & Rezai, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3129 · Cited by 289
Self-citationBurgess, A., Dubey, S., Yeung, S., Hough, O., Eterman, N., Aubert, I., & Hynynen, K. (2014) · Radiology · doi:10.1148/radiol.14140245 · Cited by 286 · cited 1×
“Animal studies have demonstrated safe and reversible BBB opening (4, 6, 7) as well as reduction of amyloidbeta plaque, neurogenesis, and improvement of memory.”
BackgroundScarcelli, T., Jordão, J. F., O’Reilly, M. A., Ellens, N. P. K., Hynynen, K., & Aubert, I. (2014) · Brain stimulation · doi:10.1016/j.brs.2013.12.012 · Cited by 163
Cited by
Applications of focused ultrasound in the brain: from thermoablation to drug delivery
Meng, Y., Hynynen, K., & Lipsman, N. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00418-z · Cited by 505
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
Rezai, A. R., D’Haese, P.-F., Finomore, V., Carpenter, J., Ranjan, M., Wilhelmsen, K., Mehta, R. I., Wang, P., Najib, U., Vieira Ligo Teixeira, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308719 · Cited by 312
Self-citationChallenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Sonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., Gomez, C., Bebawy, J. F., Liu, B. P., Bouchoux, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00112-2 · Cited by 260
Controlled tough bioadhesion mediated by ultrasound
Ma, Z., Bourquard, C., Gao, Q., Jiang, S., De Iure-Grimmel, T., Huo, R., Li, X., He, Z., Yang, Z., Yang, G., et al. (2022) · Science · doi:10.1126/science.abn8699 · Cited by 244
Metadata
- Authors
- Rezai, A. R., Ranjan, M., D’Haese, P.-F., Haut, M. W., Carpenter, J., Najib, U., Mehta, R. I., Chazen, J. L., Zibly, Z., Yates, J. R., Hodder, S. L., & Kaplitt, M.
- Affiliations
- West Virginia University (US)
- Weill Cornell Medicine (US)
- Sheba Medical Center (IL)
- Corresponding author
- Rezai, Ali R.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-04-13
- Volume
- 117
- Issue
- 17
- Pages
- 9180-9182
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7196825
- OpenAlex
- W3015813913
- Cited by
- 365
- References
- 16
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 62 · 2023: 61 · 2022: 62 · 2021: 48 · 2020: 12
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- West Virginia Clinical and Translational Science Institute
- Weill Cornell Medical College
- National Institute of General Medical Sciences (U54GM104942)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Keywords
- blood-brain barrier opening, focused ultrasound, Alzheimer's disease, hippocampus, entorhinal cortex, MR-guided ultrasound, parenchymal enhancement, early Alzheimer's disease, treatment safety and feasibility
- MeSH terms
- Ultrasonic Waves, Aged, Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Ultrasonography, Ultrasonic Therapy, Drug Delivery Systems, Microbubbles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound. https://app.cochat.ai/papers/10.1073/pnas.2002571117
- The paper
- Rezai, A. R., Ranjan, M., D’Haese, P.-F., Haut, M. W., Carpenter, J., Najib, U., Mehta, R. I., Chazen, J. L., Zibly, Z., Yates, J. R., Hodder, S. L., & Kaplitt, M. (2020). Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2002571117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.